Payment overview · 2025
General Payments
$1,427.02
81 reported records · 13 companies
Healthcare provider profile · identity verified
Jesus Presto Querubin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENUP, KY · NPI 1609965375
Verified facts
What the public records show
CMS Open Payments records show Jesus Presto Querubin, MD received $1,427.02 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Movantik, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rybelsus by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.96 | 21.9% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.01 | 18.0% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $217.52 | 15.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.42 | 13.6% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.40 | 8.7% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.82 | 6.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.03 | 4.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.62 | 3.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.00 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.12 | 2.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.06 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.35 | 1.3% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $16.71 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,427.02 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $271.71 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $235.32 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $235.32 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $217.52 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $179.16 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $132.29 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $123.40 | 7 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $85.82 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.97 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.25 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.27 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 137 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
137 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
89 | 28 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1619 | 183 |
| Oxycodone Hcl | Oxycodone Hcl | 1030 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 141 |
| Tramadol Hcl | Tramadol Hcl | 418 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 398 | 79 |
| Montelukast Sodium | Montelukast Sodium | 372 | 144 |
| Pravastatin Sodium | Pravastatin Sodium | 311 | 88 |
| Clonazepam | Clonazepam | 298 | 42 |
| Losartan Potassium | Losartan Potassium | 275 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 79 |
| Topiramate | Topiramate | 225 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 92 |
| Methylprednisolone | Methylprednisolone | 196 | 119 |
| Metformin Hcl | Metformin Hcl | 188 | 52 |
| Bupropion Xl | Bupropion Hcl | 187 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 46 |
| Diazepam | Diazepam | 170 | 25 |
| Pregabalin | Pregabalin | 161 | 23 |
| Memantine Hcl | Memantine Hcl | 158 | 51 |
| Ozempic | Semaglutide | 158 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 140 | 43 |
| Jardiance | Empagliflozin | 139 | 31 |
| Meloxicam | Meloxicam | 138 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 39 |
| Azithromycin | Azithromycin | 134 | 92 |
| Vascepa | Icosapent Ethyl | 108 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 23 |
| Trazodone Hcl | Trazodone Hcl | 90 | 25 |
| Repatha Sureclick | Evolocumab | 89 | 30 |
| Rybelsus | Semaglutide | 89 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 22 |
| Ondansetron Odt | Ondansetron | 86 | 33 |
| Omeprazole | Omeprazole | 83 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 25 |
| Lisinopril | Lisinopril | 75 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 11 |
| Linzess | Linaclotide | 65 | 20 |
| Promethazine Hcl | Promethazine Hcl | 60 | 19 |
| Colchicine | Colchicine | 59 | 18 |
| Allopurinol | Allopurinol | 57 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 51 | 14 |
| Buspirone Hcl | Buspirone Hcl | 51 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 17 |
| Vraylar | Cariprazine Hcl | 51 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 48 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 37 |
| Cefdinir | Cefdinir | 47 | 39 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 16 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 26 |
| Movantik | Naloxegol Oxalate | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 41 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 12 |
| Roflumilast | Roflumilast | 40 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 29 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 21 |
| Lactulose | Lactulose | 27 | 11 |
| Carvedilol | Carvedilol | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,427.02 · 81 records | ABBVIE INC. | AIRSUPRA, AREXVY, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, EVENITY, JARDIANCE, MOUNJARO, MOVANTIK, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Sunosi, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error